Can someone with lung nodules take Novo Nordisk's Ozempic (Semaglutide)?

Novo Nordisk's Semaglutide injection, commonly known as "Tirzepatide," may be used under a doctor's evaluation for individuals with benign pulmonary nodules who have no drug allergies and normal liver and kidney function. However, it should be avoided in cases of malignant nodules or other contraindications. If symptoms such as worsening cough, chest pain, or new respiratory issues occur after use, prompt medical attention is recommended.

Semaglutide is primarily used for the treatment of type 2 diabetes and weight management in obesity. Its pharmacological effects focus on regulating blood glucose and metabolism. There is no clear evidence that it directly causes pulmonary nodules to grow or become malignant, nor does it interfere with the diagnosis and monitoring of nodules.

However, patients with malignant pulmonary nodules should prioritize treatment of the primary disease. Using semaglutide may increase metabolic stress on the body, and some patients may have concurrent liver or kidney dysfunction, making them unsuitable candidates for safe use. Patients with benign nodules should undergo comprehensive evaluations before starting the medication and only begin treatment under medical guidance after contraindications are ruled out.

Regular follow-up imaging to monitor changes in pulmonary nodules is necessary during treatment, along with ongoing monitoring of blood glucose, liver, and kidney function. It is important to maintain a regular lifestyle, avoid fatigue, eat a balanced diet, and reduce intake of high-sugar and high-fat foods. If any adverse reactions occur, discontinue the medication immediately and consult a healthcare professional to ensure that medication use and nodule monitoring proceed simultaneously.